3 Stocks Boosting The Drugs Industry Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 38 points (0.2%) at 16,236 as of Thursday, Feb. 27, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,761 issues advancing vs. 1,149 declining with 174 unchanged.

The Drugs industry currently sits up 0.4% versus the S&P 500, which is up 0.2%. Top gainers within the industry include Jazz Pharmaceuticals ( JAZZ), up 2.7%, Valeant Pharmaceuticals International ( VRX), up 1.6%, Regeneron Pharmaceuticals ( REGN), up 1.2%, Perrigo Company ( PRGO), up 1.2% and Novartis ( NVS), up 1.0%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Intercept Pharmaceuticals ( ICPT) is one of the companies pushing the Drugs industry higher today. As of noon trading, Intercept Pharmaceuticals is up $22.67 (5.6%) to $428.78 on average volume. Thus far, 319,577 shares of Intercept Pharmaceuticals exchanged hands as compared to its average daily volume of 813,600 shares. The stock has ranged in price between $401.08-$430.99 after having opened the day at $409.97 as compared to the previous trading day's close of $406.11.

Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to treat chronic liver diseases utilizing its proprietary bile acid chemistry. Intercept Pharmaceuticals has a market cap of $7.3 billion and is part of the health care sector. Shares are up 455.2% year-to-date as of the close of trading on Wednesday. Currently there are 5 analysts who rate Intercept Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Intercept Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share and deteriorating net income. Get the full Intercept Pharmaceuticals Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

STMicroelectronics, Intercept Pharmaceuticals: 'Mad Money' Lightning Round

Watch Out For the Dominoes That Fall: Cramer's 'Mad Money' Recap (Wed 9/20/17)

Aldeyra Leaps on Data for Dry Eye Disease Treatment - Biotech Movers

Clovis Sell-Off May Be Overdone